Search Beyond News…

Hims & Hers Health faces intensifying legal scrutiny as class action lawsuits mount over alleged securities fraud

Executive summary: Robbins LLP has urged Hims & Hers Health (NYSE: HIMS) shareholders to contact the firm regarding an ongoing class action lawsuit involving securities acquired between August 4, 2025, and July 29, 2026. The lawsuit is tied to a federal complaint by the FTC regarding alleged business practices, posing significant legal and financial risks to the company's market valuation.

Who is involved: Hims & Hers Health, Inc. (NYSE: HIMS), Robbins LLP, and the Federal Trade Commission (FTC).

Likely next: Appointment of a lead plaintiff and potential discovery phases regarding the company's regulatory compliance.

The recent outreach by Robbins LLP to Hims & Hers Health shareholders signals a deepening of legal scrutiny surrounding the telehealth company. The firm is inviting investors who suffered losses to come forward as part of a securities‑fraud class action that, according to the filing, covers alleged misstatements beginning in August 2025. This suggests that plaintiffs believe the company’s disclosures during that window may have misrepresented financial performance or growth prospects, prompting a formal legal challenge. Such litigation carries tangible business implications. Beyond potential settlement costs, the lawsuit can divert management attention, increase compliance and legal‑defense expenses, and weigh on investor confidence, which may be reflected in the stock’s volatility. The process of appointing a lead plaintiff and entering discovery will likely unfold over the coming months, during which both sides will exchange documents and testimony that could clarify the scope of the alleged misstatements. Depending on the evidence uncovered, the case could settle, proceed to trial, or be dismissed, each outcome carrying distinct near‑term consequences for Hims & Hers Health’s reputation and financial outlook.

What's next — scenarios

Base: Protracted litigation and legal costs (50%)

Continued high legal expenses and management distraction for HIMS.

Downside: Significant settlement or judgment (30%)

Direct hit to cash reserves and potential impact on capital allocation.

Upside: Dismissal of claims (20%)

Market relief and restoration of investor confidence.

What to watch

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Historical parallels

Key entities

Sources

Related cases

Browse the full archive →